000298364 001__ 298364
000298364 005__ 20251202115945.0
000298364 0247_ $$2doi$$a10.1007/s00259-025-07073-w
000298364 0247_ $$2pmid$$apmid:39883139
000298364 0247_ $$2ISSN$$a1619-7070
000298364 0247_ $$2ISSN$$a1619-7089
000298364 037__ $$aDKFZ-2025-00262
000298364 041__ $$aEnglish
000298364 082__ $$a610
000298364 1001_ $$00009-0000-3837-7151$$aCalderón, Eduardo$$b0
000298364 245__ $$aOne-day dual-tracer examination in neuroendocrine neoplasms: a real advantage of low activity LAFOV PET imaging.
000298364 260__ $$aHeidelberg [u.a.]$$bSpringer-Verl.$$c2025
000298364 3367_ $$2DRIVER$$aarticle
000298364 3367_ $$2DataCite$$aOutput Types/Journal article
000298364 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1748597464_24473
000298364 3367_ $$2BibTeX$$aARTICLE
000298364 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000298364 3367_ $$00$$2EndNote$$aJournal Article
000298364 500__ $$a2025 Jun;52(7):2463-2476
000298364 520__ $$aSomatostatin receptor (SSTR)-PET is crucial for effective treatment stratification of neuroendocrine neoplasms (NENs). In highly proliferating or poorly differentiated NENs, dual-tracer approaches using additional [18F]FDG PET can effectively identify SSTR-negative disease, usually requiring separate imaging sessions. We evaluated the feasibility of a one-day dual-tracer imaging protocol with a low activity [18F]FDG PET followed by an SSTR-PET using the recently introduced [18F]SiFAlin-TATE tracer in a long axial field-of-view (LAFOV) PET/CT scanner and its implications in patient management.Twenty NEN patients were included in this study. Initially, a low activity [18F]FDG PET was performed (0.5 ± 0.01 MBq/kg; PET scan 60 min p.i.). After 4.2 ± 0.09 h after completion of the [18F]FDG PET, a standard activity of [18F]SiFAlin-TATE was administered (3.0 MBq/kg; PET scan 90 min p.i.). To ensure the quantification accuracy of the second scan, we evaluated the potential impact of residual [18F]FDG activity by segmenting organs with minimal physiological SSTR-tracer uptake, such as the brain and myocardium, and assessing the activity concentrations (ACTs) of tumor lesions. Residual tumor lesion ACTs of [18F]FDG were calculated by factoring fluorine-18 decay, identifying a maximum residual ACT of 15% (R15%). To account for increased [18F]FDG trapping over time, higher residual ACTs of 20% (R20%) were considered. These simulated [18F]FDG ACTs were compared with those measured in the second PET scan with [18F]SiFAlin-TATE. The influence of the dual-tracer PET/CT results on therapeutic strategies was evaluated.[18F]FDG cerebral uptake significantly decreased in the subsequent SSTR-PET (mean uptake [18F]FDG: SUVmean 6.0 ± 0.4; mean uptake in [18F]SiFAlin-TATE PET: SUVmean 0.2 ± 0.01; p < 0.0001); with similar results recorded for the myocardium. Simulated residual [18F]FDG ACTs represented only a minimal percentage of ACTs measured in the tumor lesions from the second PET scan (R15%: mean 5.2 ± 0.9% and R20%: mean 6.8 ± 1.2%), indicating only minimal residual activity of [18F]FDG that might interfere with the second PET scan using [18F]SiFAlin-TATE and preserved semi-quantification of the latter. Dual-tracer PET/CT findings directly influenced changes in therapy plans in eleven (55%) of the examined patients.LAFOV PET scanners enable a one-day dual-tracer protocol, providing diagnostic image quality while preserving the semi-quantification of two 18F-labeled radiotracers, potentially simplifying the assessment of tumor biology and improving the clinical patient management while reducing logistical challenges. Additionally, low-activity PET imaging facilitates one-day dual-tracer PET examinations.
000298364 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000298364 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000298364 650_7 $$2Other$$aDual-tracer PET
000298364 650_7 $$2Other$$aLAFOV PET/CT
000298364 650_7 $$2Other$$aLow activity [18F]FDG PET
000298364 650_7 $$2Other$$aNeuroendocrine neoplasms
000298364 7001_ $$aKiefer, Lena S$$b1
000298364 7001_ $$aSchmidt, Fabian P$$b2
000298364 7001_ $$aLan, Wenhong$$b3
000298364 7001_ $$aBrendlin, Andreas S$$b4
000298364 7001_ $$aReinert, Christian P$$b5
000298364 7001_ $$aSinger, Stephan$$b6
000298364 7001_ $$aReischl, Gerald$$b7
000298364 7001_ $$aHinterleitner, Martina$$b8
000298364 7001_ $$aDittmann, Helmut$$b9
000298364 7001_ $$00000-0001-7519-0417$$ala Fougère, Christian$$b10
000298364 7001_ $$00000-0003-3397-6299$$aTrautwein, Nils F$$b11
000298364 773__ $$0PERI:(DE-600)2098375-X$$a10.1007/s00259-025-07073-w$$n7$$p2463-2476$$tEuropean journal of nuclear medicine and molecular imaging$$v52$$x1619-7070$$y2025
000298364 8564_ $$uhttps://inrepo02.dkfz.de/record/298364/files/s00259-025-07073-w.pdf$$yOpenAccess
000298364 8564_ $$uhttps://inrepo02.dkfz.de/record/298364/files/s00259-025-07073-w.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000298364 909CO $$ooai:inrepo02.dkfz.de:298364$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000298364 9101_ $$0I:(DE-588b)2036810-0$$60000-0001-7519-0417$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000298364 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000298364 9141_ $$y2025
000298364 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-05
000298364 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-05
000298364 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-05
000298364 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-05
000298364 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J NUCL MED MOL I : 2022$$d2024-12-05
000298364 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-05
000298364 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-05$$wger
000298364 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-05
000298364 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000298364 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-05
000298364 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J NUCL MED MOL I : 2022$$d2024-12-05
000298364 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-05
000298364 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-05
000298364 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-05
000298364 9201_ $$0I:(DE-He78)TU01-20160331$$kTU01$$lDKTK Koordinierungsstelle Tübingen$$x0
000298364 980__ $$ajournal
000298364 980__ $$aVDB
000298364 980__ $$aUNRESTRICTED
000298364 980__ $$aI:(DE-He78)TU01-20160331
000298364 9801_ $$aFullTexts